Novartis: Graft vs Host Disease trials

The registry lists 12 Graft vs Host Disease studies with Novartis as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 1Phase 2 2Phase 3 3Phase 4 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Ruxolitinib in Patients With Graft-Versus Host DiseaseRecruitingNCT07594587
• Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host DiseaseRecruitingNCT06824103Phase 4
• Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell TransplantCompletedNCT03774082Phase 2Results posted
• Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host DiseaseCompletedNCT03491215Phase 1/2Results posted
• Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell TransplantationCompletedNCT02913261Phase 3Results posted
• SCHEDULE Follow Up Visit 5-7 yrCompletedNCT02864706Phase 4Results posted
• A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.CompletedNCT02040584Phase 3Results posted
• 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant PatientsCompletedNCT01843348Phase 3Results posted
• Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant RecipientsCompletedNCT01649427Phase 4Results posted
• Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host DiseaseActive, not recruitingNCT06462469Phase 4
• A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in KoreaCompletedNCT05621733
• CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4